Lowest Price Guaranteed
Slides
207
Last Updated
July 2026
View Count
14429
The global orphan drug market size is expected to grow from USD 236.27 billion in 2025 to reach USD 667.48 billion by 2035, representing a CAGR of 10.94% over the forecast period.
 |
To learn more about this report, request a free sample copy
The new market report provides comprehensive information about current market landscape, industrial players, market drivers, challenges, future growth scenarios, and SWOT analysis.
Orphan drugs are therapeutic products that are specifically designed to diagnose, prevent and treat rare disease indications. These drugs are named orphan drugs since the pharmaceutical companies develop these drugs in order to treat patients suffering from rare disease indication for which no treatment or lesser numbers of drugs are available beyond marketing interest.
With rising risk of rare diseases and some rare oncological disorders, the demand for orphan drugs has significantly increased to treat patients. A recent report published by National Center for Advancing Translational Sciences highlighted that nearly 10,000 rare diseases affect the US population. Moreover, according to International Agency for Research on Cancer (IARC), nearly 25% of all the cancer cases diagnosed are rare cancers.
Considering the ongoing risk of diseases, several industrial players are focusing on the development of orphan drugs for diagnosis, prevention and treatment of various disease indications. It is important to highlight here, the USFDA also grants orphan drug designation to the biological / drug products for the prevention, diagnosis and treatment of rare disease conditions. The flexibility given for the production of orphan drugs has catered the attention of several industrial players to take strategic initiatives in this field.
Further, it is also important to highlight here that in 2024, several orphan drugs received approval from the USFDA. These include approval of” KEBILIDI™ (an AAV vector based gene therapy for AADC deficiency; accelerated approval), Aucatzyl® (a CAR T cell therapy for relapsed / refractory adult B-cell acute lymphoblastic leukemia), TECELERA (a TCR therapy for unresectable or metastatic synovial sarcoma) and Asciminib® (for Philadelphia chromosome-positive chronic myeloid leukemia; accelerated approval). Owing to the rising approval of therapeutic drugs, several industrial players has accelerated the development of orphan drugs (including biologics) to treat patients with rare disease indications.
In December 2024, Exegenesis Bio announced that the USFDA granted orphan drug designation to EXG110, a gene therapy for Fabry disease. As stated by Dr. Zhenhua Wu (CEO, Exegenesis Bio), “Our unique approach to wAMD is built on three pillars: targeting multiple pathways involved in neovascular disease, including VEGF subtypes A, B, C, D and Angiopoietin 2; packaging our cargo in a proprietary capsid that targets photoreceptors and retinal pigment epithelium more efficiently, and administering the treatment by intravitreal injection, a safe, non-surgical procedure.” Considering the aforementioned milestones, we believe orphan drug market will continue to gain momentum during the forecast period.
The research report provides invaluable information about industrial players who are presently active across various segments of the industry as mentioned in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2035 | $667.48 Billion | |
| CAGR | 10.94% | |
| Type of Drug |
|
|
| Type of Therapeutic Area |
|
|
| Type of Indication |
|
|
| Type of Sale |
|
|
| Type of Distribution Channel |
|
|
| Geographical Regions |
|
|
| Key Drugs |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of the orphan drug market report was to estimate the current size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
The market analysis also features the likely distribution of the current and forecasted opportunity within the market distributed across various segments, such as type (biologics and non-biologics), type of therapeutic area (oncologic disorders, metabolic disorders, hematologic and immunologic disorders, infectious disorders, neurological disorders, other therapeutic areas), type of indication (non-hodgkin lymphoma, acute myeloid leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, duchenne muscular dystrophy, renal cell carcinoma, graft vs host disease, other indications), type of sale (generics and prescribed), type of distribution channel (hospital pharmacies, retail pharmacies, online sales, and other distribution channels), key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America), leading players and key drugs.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three orphan drug market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on the type of drug, the global orphan drug market size is segmented into biologics and non-biologics. Currently, biologics holds the highest share (nearly 70%) of the market and the trend of dominance is likely to remain unchanged during the forecast period. This can be attributed to the fact that majority of the approved orphan drugs for the treatment of rare diseases have been developed using biologics.
Moreover, biologics, such as monoclonal antibodies, immune modulators and regenerative medicine have the potential to target wide range of disease indication. Additionally, the increasing research on biologics conducted by biopharmaceutical CROs has further contributed to the highest share of the market and this segment is likely to grow at a higher CAGR during the forecast period.
This segment highlights the distribution of global orphan drug market based on therapeutic area into oncologic disorders, metabolic disorders, hematologic and immunologic disorders, infectious disorders, neurological disorders, and other therapeutic areas. Currently, oncological disorders account for the largest share (nearly 50%) of the market driven by the growing prevalence of cancer across the globe.
The alarming increase in the number of patients worldwide has surge the demand for orphan drugs to treat oncological disorders. Additionally, a number of drugs are being approved for the treatment of rare cancers. Notably, in August 2024, TECELERA received approval from the FDA to treat patients with unresectable or metastatic synovial sarcoma.
However, in the long run, neurological disorders segment is expected to grow at a higher CAGR during the forecast period. This can be attributed to the availability of wide range of orphan drugs for the treatment of neurological diseases. One such example is SKYSONA® (Elivadogene autotemcel) (developed by bluebird bio) and approved in September 2022 in order to slower down progression of neurological dysfunction in male patients (4-17 years old) with early active cerebral adrenoleukodystrophy.
On the basis of type of indication. The global market is segmented into non-Hodgkin lymphoma, acute myeloid leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, duchenne muscular dystrophy, renal cell carcinoma, graft vs host disease and other indications.
According to our study, non-Hodgkin lymphoma segment accounts for the highest orphan drug market share. This can be attributed to the fact that, non-Hodgkin is a complex disease consisting of various sub-types, which cannot be treated with traditionally available drug. This complexity has necessitated the demand for orphan drugs to meet the unmet treatment requirements.
However, in the long run, renal cell carcinoma is anticipated to register a higher CAGR during the forecast period. This can be attributed to the increasing research and development activities to develop advanced therapeutic drugs for the treatment of renal cancer. It is worth mentioning that, in April 2024, National Medical Products Administration (NMPA) approved Toripalimab Plus Axitinib, for the treatment of metastatic renal cell carcinoma.
The market for orphan drugs is categorized based on type of sale into generic and prescribed. Currently, generic sale occupies the highest share of the market driven by the cost-effectiveness and rising approval of generic drugs for the treatment of wide range of disease indication. It is important to highlight here that with growing expiration of branded drugs or patent drugs, there has been surge in the generic drugs sales, which is expected to be the significant reason for highest share. Driven by the growing demand, this segment is expected to grow at a higher CAGR during the forecast period.
Based on the distribution channel, the global market is further bifurcated into hospital pharmacies, retail pharmacies, online sales, and other distribution channels. It is worth noting here that hospital pharmacies presently account for the largest orphan drug market share (42%).
This dominance is due to the fact that a large number of orphan drugs are generally administered into the hospitals intravenously under the healthcare experts. However, it is worth noting here that online pharmacy is expected to grow at a higher CAGR during the forecast period. This can be attributed to the fact that online pharmacies offer convenience of purchasing and are more affordable than the offline market.
The global orphan drug market is distributed across different geographical regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our analysis, currently, North America accounts for the largest share (49%) of the market. North America is primarily due to the supportive guidelines offered by the regulatory approval and rising research on the orphan drugs specifically for the treatment of cancer and rare diseases. Furthermore, the large pool of patients with chronic conditions and presence of established players who are presently increasing their research efforts for the development of orphan drugs has contributed to the growth of the market.
However, in the long run, Asia-Pacific is expected to register the highest CAGR during the forecast period. Currently, Asia-Pacific region is experiencing an upsurge in the chronic diseases burden including respiratory disorders, cardiovascular disorders and endocrinology disorders. The increasing prevalence of diseases in Asian countries has underscored the demand for advanced orphan drugs to treat patients, which is likely to be a key growth factor of the market in this region.
Some of the key orphan drugs include Revlimid®, Rituxan®, Opdivo®, Keytruda®, Imbruvica®, Soliris®, Jakaf®, Pomalyst®, Darzalex®, Spinraza®, and Adcetris®. According to our analysis, Keytruda® is the leader by a huge margin, with Merck reporting sales of USD 25.011 billion in FY 2023. It is followed by Opdivo®, which is the second highest selling drug as it is widely adopted for the treatment of renal cell carcinoma, esophageal cancer, gastroesophageal junction cancer and urothelial carcinoma. Opdivo generated sales of USD 10 billion in 2023 for Bristol Myers Squibb and its partner Ono Pharmaceutical.
The “Orphan Drug Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market size and future opportunities associated with companies within the orphan drugs industry, during the given forecast period. Key takeaways of the market report are briefly discussed below.
Currently, the global market landscape of orphan drugs is witnessing the presence of several well-established industrial leaders who are currently engaged in this industry. With increasing acceptance of orphan drugs for the treatment of genetic diseases, the market is continually gaining traction making the field investible for long term. In order to leverage competitive edge, several industrial players are focusing on strategic initiatives to expand research on orphan drugs and approval from the USFDA. Overall, the market seems highly competitive, featuring several small, mid-sized and large companies.
One of the potential market drivers that is propelling the orphan drug market is rising prevalence of rare disease across the globe. Notably, the rare diseases, such as Waardenburg Syndrome, Stoneman Syndrome and Von Hippel Lindau Syndrome has very limited treatment options. Hence, limited availability of treatment has necessitated the demand for advanced orphan drugs to address these diseases. Furthermore, the growing research and development activities from industrial leaders on innovative drugs has contributed to the growth of the market during the forecast period. In September 2024, Novo Nordisk inked a deal with NanoVation Therapeutics for the advancement in development of genetic medicines for rare and cardiometabolic diseases, using latter’s proprietary long-circulating lipid nanoparticle technology (lcLNP™).
US FDA granted orphan drug designation to 2,088 candidates during a period of 5 years from 1 January 2020-1 January 2025. During the same duration, 704 drugs were granted orphan designation by the EMA.
Some of the potential market challenges that hinder industry growth include high cost associated with drug research and development. Further, industrial leaders are required to adhere with stringent guidelines provided by the regulatory authorities. These complex guidelines may delay the approval of orphan drugs, posing a significant barrier for the market players. However, with the advent of artificial intelligence, it is anticipated that the cost of drug development will reduce as compared to conventional drug discovery methods. Additionally, lack of awareness about orphan drugs among physicians and patients may impede the adoption of orphan drugs in the market.
Some of the major orphan drug market growth factors include rising partnerships between industrial players and high demand for personalized therapeutic drugs. With the rising prevalence of rare and genetic disorders, the industrial players are focusing on personalized therapeutics that will be designed based on individual genome profile. For instance, in February 2024, Rapid Commercialization Partners and Orphan signed a strategic partnership for the development and commercialization of orphan drugs and therapies. Along with industrial players several government organizations are currently undertaking strategic initiatives to support research of orphan drugs.
As a part of such initiatives, in August 2023, Indian government announced a scheme to promote research on advanced drugs by pharmaceutical companies, offering INR 5000 crore for over five years till 2028 to the pharmaceutical medication technology (medtech sector) for reducing dependency on importing therapeutic products such as orphan drugs to treat rare diseases. Under this scheme, nine orphan drug manufacturers and medical device developers will be selected to enhance research in six areas. These ongoing initiatives by industrial players and government organizations are the key growth factors that are anticipated to drive the market during the forecast period.
Presently, the market for orphan drugs is valued at USD 236.27 billion and is poised to reach 667.48 billion by 2035. This significant trajectory is likely to be the result of growing demand for personalized drugs to target rare diseases. It is important to highlight here that North America currently holds the dominating position driven by the favorable drug approval guidelines. Furthermore, the region has robust presence of industrial players who are constantly accelerating their research to develop orphan drugs. For instance, in September 2024, Ractigen Therapeutics received orphan drug designation for its RAG-18 (an investigational small activating RNA (saRNA)) drug by the FDA. The drug is presently under preclinical development stage for the treatment of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). Driven by the increasing approval of the orphan drugs, we believe that the market will continue to grow at a CAGR of 10.94% during the forecast period.
Examples of key players engaged in the development and commercialization of orphan drugs (which have also been captured in this report, arranged in alphabetical order) include Alexion Pharmaceuticals, Amgen, Biogen, Bristol-Myers Squibb, Celldex Therapeutics, GSK, Eisai, Eli Lilly, Johnson & Johnson, Kyowa Kirin, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Takeda Pharmaceutical and Vertex Pharmaceuticals. This market report includes an easily searchable excel database of all the orphan drugs developers worldwide.
Several recent developments have taken place in the field of orphan drugs, some of which have been outlined below.